The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma

Journal of Translational Medicine

Poster Presentation

Letizia Porcelli¹  Stefania Tommasi¹  Anna E. Quatrale¹  Imma Maida¹  Rosa M Iacobazzi¹  Tiziana Cocco²  Anna Ferretta²  Diana A Stolfa³  Gabriella Guida³  Stefania Guida³  Claudia Grieco³  Michele Guida⁴  Sabino Strippoli⁴ 

[1] Clinical Experimental Oncology Laboratory, Istituto Tumori Giovanni Paolo II, Bari, Italy;Department of Medical Biochemistry, Biology & Physics, University of Bari 'A. Moro', 70124, Bari, Italy;Dept. of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari 'A. Moro', 70124, Bari, Italy;Medical Oncology Department, Istituto Tumori Giovanni Paolo II, Bari, Italy;

关键词: Metastatic Melanoma;    Vemurafenib;    BRAF Inhibitor;    Dabrafenib;    BRAF Gene;   

DOI  :  10.1186/1479-5876-13-S1-P3

来源: Springer

【 授权许可】

Unknown   
© Porcelli et al; licensee BioMed Central Ltd. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.